Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus.

Abstract

Rubella is a highly contagious viral infection that usually causes a mild disease in children and adults. However, infection during pregnancy can result in a fetal or newborn death or congenital rubella syndrome (CRS), a constellation of permanent birth defects including cataracts, heart defects, and sensorineural deafness. The live-attenuated rubella vaccine has been highly effective, with the Americas declared free of endemic rubella transmission in 2015. However, rubella remains a significant problem worldwide and the leading cause of vaccine-preventable birth defects globally. Thus, elimination of rubella and CRS is a goal of the World Health Organization. No specific therapeutics are approved for the rubella virus. Therefore, we set out to identify whether existing small molecules may be repurposed for use against rubella virus infection. Thus, we performed a high-throughput screen for small molecules active against rubella virus in human respiratory cells and identified two nucleoside analogs, NM107 and AT-527, with potent antiviral activity. Furthermore, we found that combining these nucleoside analogs with inhibitors of host nucleoside biosynthesis had synergistic antiviral activity. These studies open the door to new potential approaches to treat rubella infections.

• Authors: Mark Dittmar, Kanupriya Whig, Jesse Miller, Brinda Kamalia, Suganthi Suppiah, Ludmila Perelygina, Kathleen E Sullivan, David C Schultz, Sara Cherry
• Journal: PNAS nexus (PNAS Nexus) Vol. 2 Issue 9 Pg. pgad256 (Sep 2023) ISSN: 2752-6542 [Electronic] England
• PMID: 37674858 (Publication Type: Journal Article)
• Copyright: © The Author(s) 2023. Published by Oxford University Press on behalf of National Academy of Sciences.